Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Depression 6Breast Neoplasms 4Anxiety Disorders 4Pain, Postoperative 3Pain 3Carcinoma, Hepatocellular 2Spinal Cord Neoplasms 1Sleep Initiation and Maintenance Disorders 1Sleep Deprivation 1Ovarian Neoplasms 1Breast Cancer Surgery 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 101liposomal doxorubicin 100Cyclophosphamide 96Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 40Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × Esketamine × Clear all
NCT06624878 2026-02-27

Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

Zhejiang Cancer Hospital

Phase NA Completed
568 enrolled
Gynecologic

Depression, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡